Trastuzumab, a humanized monoclonal antibody, interferes with the HER2/neu receptor and is mainly used to treat certain breast cancers, especially HER2-positive metastatic breast cancer. Combined with chemotherapy, trastuzumab increases both survival and response rate.There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1, HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, the HER receptors embedded in the cell membrane promote cell growth and division by turning genes on and off. The HER2 pathway stimulates cell proliferation if it normally functions, when HER2 is overexpressed, cell growth accelerates beyond its normal limits, which happens in some cancers, notably certain types of breast cancer.
Cross-Reactivity: <1EU/mg (<0.001EU/µg)Determined by LAL gel clotting assay
Human ErbB2/HER2 ELISA Standard Curve. Direct ELISA binding curve demonstrating the recognition of Human Anti-Human ErbB2/HER2 (Research Grade Trastuzumab Biosimilar) Monoclonal Antibody to ErbB2/HER2. The target protein was coated onto the microplate Well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.
* VAT and and shipping costs not included. Errors and price changes excepted
